Siemens expands preclinical alliance

Article

The scope of a marketing agreement that allows Siemens Medical Solutions to market Gamma Medica's molecular imaging animal scanner has been expanded to cover worldwide markets. The two companies began their alliance last July when Siemens obtained U.S.

The scope of a marketing agreement that allows Siemens Medical Solutions to market Gamma Medica's molecular imaging animal scanner has been expanded to cover worldwide markets. The two companies began their alliance last July when Siemens obtained U.S. marketing rights for the scanner. The expanded agreement covers X-SPECT, Gamma Medica's second-generation MicroSPECT system. This dual-modality system for preclinical imaging combines SPECT with CT. Designed for in vivo imaging of small animals, it is used primarily in the study of disease processes and for drug development.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.